Clinical features of EAE in male and female WT and PPAR-δ−/− mice.
| Clinical feautres | WT male | PPAR-δ−/− male | WT female | PPAR-δ−/− female |
| Maximum score | ||||
| Experiment 1 | 2.9 (0.5) | 2.9 (0.2) | 2.4 (0.3) | 3.3 (0.6) |
| Experiment 2 | 2.9 (0.1) | 2.9 (0.2) | 3.3 (0.2) | 3.3 (0.3) |
| Death from disease | ||||
| Experiment 1 | 1/9 | 0/7 | 0/9 | 2/6 |
| Experiment 2 | 0/10 | 2/9 | 0/9 | 1/11 |
| Incidence | ||||
| Experiment 1 | 8/9 | 7/7 | 9/9 | 6/6 |
| Experiment 2 | 10/10 | 9/9 | 9/9 | 11/11 |
| Day of onset | ||||
| Experiment 1 | 12.4 (0.5) | 13.6 (1.0) | 14.6 (1.4) | 12.3 (0.4) |
| Experiment 2 | 8.3 (0.1) | 10.9 (0.8)a | 11.0 (0.3) | 11.4 (0.8) |
| Number of mice remitting to score 0 | ||||
| Experiment 1 | 7/7 (100%) | 2/7 (28%) | 9/9 (100%) | 3/6 (50%) |
| Experiment 2 | 8/10 (80%) | 1/9 (11%) | 8/9 (89%) | 6/11 (54%) |
| Clinical feautres | WT male | PPAR-δ−/− male | WT female | PPAR-δ−/− female |
| Maximum score | ||||
| Experiment 1 | 2.9 (0.5) | 2.9 (0.2) | 2.4 (0.3) | 3.3 (0.6) |
| Experiment 2 | 2.9 (0.1) | 2.9 (0.2) | 3.3 (0.2) | 3.3 (0.3) |
| Death from disease | ||||
| Experiment 1 | 1/9 | 0/7 | 0/9 | 2/6 |
| Experiment 2 | 0/10 | 2/9 | 0/9 | 1/11 |
| Incidence | ||||
| Experiment 1 | 8/9 | 7/7 | 9/9 | 6/6 |
| Experiment 2 | 10/10 | 9/9 | 9/9 | 11/11 |
| Day of onset | ||||
| Experiment 1 | 12.4 (0.5) | 13.6 (1.0) | 14.6 (1.4) | 12.3 (0.4) |
| Experiment 2 | 8.3 (0.1) | 10.9 (0.8)a | 11.0 (0.3) | 11.4 (0.8) |
| Number of mice remitting to score 0 | ||||
| Experiment 1 | 7/7 (100%) | 2/7 (28%) | 9/9 (100%) | 3/6 (50%) |
| Experiment 2 | 8/10 (80%) | 1/9 (11%) | 8/9 (89%) | 6/11 (54%) |
Values are means + SEM.
Significant difference from sex-matched WT counterpart